Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.

Toshirou FukushimaYuuki WakatsukiTakashi KobayashiKei SoneharaKazunari TateishiManabu YamamotoTakeshi MasubuchiFumiaki YoshiikeKazuya HiraiTsutomu HachiyaTomonobu Koizumi

Published in: Cancer chemotherapy and pharmacology (2018)

The combination of cisplatin/pemetrexed/bevacizumab followed by pemetrexed/bevacizumab maintenance therapy exhibited favorable efficacy and manageable toxicity profiles in patients with EGFR-wild type non-squamous NSCLC (UMIN-CTR number: UMIN000003645).

Keyphrases

small cell lung cancer
metastatic colorectal cancer
phase ii study
advanced non small cell lung cancer
wild type
brain metastases
epidermal growth factor receptor
high grade
low grade
open label
oxidative stress
clinical trial
stem cells
cell therapy
study protocol